BioNTech entered the week with two distinctly different narratives competing for investors’ attention. A European court invalidated a patent claim that had hung over its Covid-19 vaccine franchise, while a major meta-analysis in The Lancet reaffirmed the clinical power of the mRNA platform at the heart of its oncology ambitions. Yet neither development was enough to stop Morningstar from downgrading the stock to “overvalued” territory or to prevent Morgan Stanley from trimming its price target.
The legal victory came on Wednesday before the Unified Patent Court. A senate chaired by Judge Daniel Voß ruled that European patent EP 2 401 365 is invalid for lack of novelty, rejecting Promosome’s infringement allegations against BioNTech and its partner Pfizer. The court acknowledged Promosome’s standing to sue, but found no evidence that the patent had been violated. The decision mirrors a similar case in the United States, where a comparable claim was dismissed with prejudice in 2023. Promosome can still appeal, though the ruling raises the bar for any future patent challenges in Europe.
At the same time, the stock’s recent rally has prompted a reassessment from Morningstar. In its weekly scan of U.S.-listed equities for the week ending July 2, the research house slapped a 2-star rating on BioNTech, placing it among the five largest companies by market cap that slipped into overvaluation territory. The system is straightforward: 4 or 5 stars signal undervaluation, 3 stars fair value, and 1 or 2 stars mean the shares are pricing in too much optimism. The downgrade follows a 30-day run that lifted the stock by 11.33%, leaving it 3.50% above its 50-day moving average of €79.76. On Tuesday the shares had closed at €82.55, practically flat week-on-week.
Morgan Stanley, meanwhile, took a more nuanced step. The bank lowered its price target on BioNTech’s American depositary receipts to $119 from $126, though it kept its “Overweight” rating intact. The analysts cited the broader sensitivity of the biotech sector to macroeconomic factors, noting that a lower interest rate environment should benefit growth-oriented firms with long-duration research pipelines.
By midweek, the stock had slipped to €81.25, down 1.52% from the prior day. At that level it was trading roughly 5% below its 200-day moving average of €85.23, underscoring a still-fragile medium-term trend. From the January record high of €105.80, the shares remain about 23% off the peak. Over the past twelve months the decline measures 13.29%, though the year-to-date performance is essentially flat at +0.06%.
Should investors sell immediately? Or is it worth buying BioNTech?
The contrasting signals from analysts and science come as BioNTech executes a sweeping corporate transformation. The company is shifting vaccine production to Pfizer and plans to close several manufacturing sites in Germany by 2027. The restructuring will hit Idar-Oberstein, Marburg, Singapore, and former CureVac locations, affecting as many as 1,860 jobs. An efficiency programme aims to generate recurring annual savings of roughly €500 million by 2029 — capital that will be redirected toward oncology programmes.
The financial toll of the transition was laid bare in first-quarter results for 2026. Revenue shrank to €118.1 million from €182.8 million a year earlier as demand for Covid-19 shots continued to normalise, and the net loss widened to €531.9 million. For the full year, management reaffirmed guidance of €2.0 to €2.3 billion in total revenue, with research spending of €2.2 to €2.5 billion and selling, general and administrative costs between €700 million and €800 million. The company ended March with €16.8 billion in cash and securities, and has authorised a share buyback of up to $1 billion over the next twelve months.
The Lancet meta-analysis provides a scientific counterweight to the near-term financial pressure. It describes mRNA vaccines as a transformative advance in vaccinology, citing rapid development times, scalable manufacturing and strong immunogenicity alongside a favourable safety profile — all validated by the billions of doses administered during the pandemic. One of the analyses cited shows 87% efficacy against documented Covid-19 infections and 94% efficacy against deaths when measured two to six weeks after vaccination.
For BioNTech, the study’s conclusions are more than academic. A proven safety track record for the mRNA platform is a prerequisite for the cancer vaccines the company is betting on. The same platform that delivered the pandemic shot now underpins a pipeline of oncology candidates, and researchers at MIT and Harvard are exploring whether future mRNA therapeutics could be administered via microneedle patches, potentially eliminating the need for complex cold chains.
The patent ruling, meanwhile, offers breathing room on the vaccine side even as BioNTech downplays its importance. The European Commission recently approved a supply agreement for up to 300 million doses of the Covid shot, so the product line is hardly disappearing. But the strategic centre of gravity has clearly pivoted. The company is pouring its resources into oncology, and the coming quarters will test whether the market’s current valuation — or the analysts’ caution — is the more accurate read on what lies ahead. Elevated volatility, annualised at 31.76% over 30 days, and a neutral 14-day relative strength index of 56.4 suggest the stock remains in a holding pattern, waiting for the next catalyst from the clinic.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 8 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 8.
BioNTech: Buy or sell? Read more here...
